Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$20.52 +1.1%	$21.00	$17.24 ▼ $28.56	$13.02B	0.94	1.23 million shs	1.43 million shs
SMMT Summit Therapeutics	$22.61 -7.9%	$22.72	$7.23 ▼ $36.91	$18.23B	-1.01	3.72 million shs	4.35 million shs
TEVA Teva Pharmaceutical Industries	$16.84 -1.0%	$17.03	$12.47 ▼ $22.80	$19.51B	0.6	10.28 million shs	9.69 million shs
TLX Telix Pharmaceuticals	$15.48 -3.7%	$16.81	$13.61 ▼ $30.36	$5.44B	N/A	28,752 shs	54,654 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	+0.54%	-0.68%	-7.57%	+14.13%	-19.66%
SMMT Summit Therapeutics	-7.13%	+6.25%	+9.81%	+35.88%	+212.29%
TEVA Teva Pharmaceutical Industries	-1.23%	+0.48%	-5.18%	+24.42%	+2.68%
TLX Telix Pharmaceuticals	-3.99%	-3.67%	-7.69%	+8.18%	+1,547,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.8379 of 5 stars	3.3	5.0	0.0	0.0	2.0	0.0	3.1
SMMT Summit Therapeutics	2.4602 of 5 stars	4.4	1.0	0.0	0.0	1.9	1.7	0.0
TEVA Teva Pharmaceutical Industries	4.1729 of 5 stars	4.6	3.0	0.0	0.0	2.8	1.7	1.9
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.67	Moderate Buy	$37.60	83.24% Upside
SMMT Summit Therapeutics	2.79	Moderate Buy	$34.67	53.32% Upside
TEVA Teva Pharmaceutical Industries	3.22	Buy	$24.13	43.26% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.33	44.27% Upside

Current Analyst Ratings Breakdown

Latest TLX, TEVA, SMMT, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
7/1/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
7/1/2025	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/12/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
6/5/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.12B	4.21	$1.53 per share	13.39	$8.04 per share	2.55
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.53 per share	N/A
TEVA Teva Pharmaceutical Industries	$16.54B	1.17	$3.33 per share	5.06	$4.74 per share	3.55
TLX Telix Pharmaceuticals	$516.72M	10.14	$0.11 per share	140.73	$1.12 per share	13.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.76	11.66	11.53	6.69	35.11%	18.08%	14.52%	8/14/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.40	0.87	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	32.25	N/A	N/A	N/A	N/A	N/A

Latest TLX, TEVA, SMMT, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	N/A	N/A	N/A	$4.34 billion	N/A
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.34	5.32
SMMT Summit Therapeutics	N/A	10.63	10.63
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74
TLX Telix Pharmaceuticals	0.99	2.78	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.55%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	2,682	641.22 million	631.35 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable
TLX Telix Pharmaceuticals	N/A	338.38 million	N/A	N/A

TLX, TEVA, SMMT, and GMAB Headlines

Recent News About These Companies

HC Wainwright Begins Coverage on Telix Pharmaceuticals (NASDAQ:TLX)

July 5 at 2:01 AM | americanbankingnews.com

Telix Pharmaceuticals Stock Short Interest Report | NASDAQ:TLX - Benzinga

July 3, 2025 | benzinga.com

HC Wainwright & Co. Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Buy Recommendation

July 3, 2025 | msn.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What Happened

July 3, 2025 | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Coverage Initiated at HC Wainwright

July 3, 2025 | marketbeat.com

Up 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'

June 30, 2025 | msn.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Still a Buy?

June 29, 2025 | americanbankingnews.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - Here's What Happened

June 27, 2025 | marketbeat.com

Telix Pharmaceuticals Limited: Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses

June 25, 2025 | finanznachrichten.de

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?

June 23, 2025 | marketbeat.com

Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT

June 23, 2025 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?

June 20, 2025 | marketbeat.com

Telix Precision Medicine Announces AlFluor Radiochemistry Platform

June 20, 2025 | globenewswire.com

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

June 19, 2025 | globenewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Stock Price Down 6.7% - Time to Sell?

June 13, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Time to Buy?

June 12, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares' (TLX) "Outperform" Rating Reaffirmed at Wedbush

June 12, 2025 | marketbeat.com

Wedbush Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Outperform Recommendation

June 5, 2025 | msn.com

Telix Investor Day in New York City on June 11, 2025: Presenting KOLs

June 3, 2025 | globenewswire.com

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

May 7, 2025 | globenewswire.com

Shareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLX

May 7, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX, TEVA, SMMT, and GMAB Company Descriptions

Genmab A/S NASDAQ:GMAB

$20.52 +0.22 (+1.08%)

As of 07/7/2025 04:00 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Summit Therapeutics NASDAQ:SMMT

$22.61 -1.94 (-7.90%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$22.75 +0.14 (+0.62%)

As of 07/7/2025 07:59 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$16.84 -0.17 (-1.00%)

Closing price 07/7/2025 03:59 PM Eastern

Extended Trading

$16.90 +0.07 (+0.39%)

As of 07/7/2025 06:40 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Telix Pharmaceuticals NASDAQ:TLX

$15.48 -0.59 (-3.67%)

As of 07/7/2025 04:00 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time